Your browser doesn't support javascript.
loading
Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib.
de Weerdt, Iris; Hofland, Tom; Lameris, Roeland; Endstra, Sanne; Jongejan, Aldo; Moerland, Perry D; de Bruin, Renee C G; Remmerswaal, Ester B M; Ten Berge, Ineke J M; Liu, Nora; van der Stelt, Mario; Faber, Laura M; Levin, Mark-David; Eldering, Eric; Tonino, Sanne H; de Gruijl, Tanja D; van der Vliet, Hans J; Kater, Arnon P.
Afiliação
  • de Weerdt I; Department of Hematology and.
  • Hofland T; Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Lameris R; Department of Hematology and.
  • Endstra S; Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Jongejan A; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam Infection & Immunity Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Moerland PD; Department of Hematology and.
  • de Bruin RCG; Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Remmerswaal EBM; Department of Clinical Epidemiology, Biostatistics and Bioinformatics and.
  • Ten Berge IJM; Department of Clinical Epidemiology, Biostatistics and Bioinformatics and.
  • Liu N; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam Infection & Immunity Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • van der Stelt M; Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Faber LM; Renal Transplant Unit, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Levin MD; Renal Transplant Unit, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Eldering E; Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands.
  • Tonino SH; Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands.
  • de Gruijl TD; Internal Medicine, Rode Kruis Hospital, Beverwijk, The Netherlands.
  • van der Vliet HJ; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands; and.
  • Kater AP; Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Blood ; 132(21): 2260-2272, 2018 11 22.
Article em En | MEDLINE | ID: mdl-30213872
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Linfócitos T Citotóxicos / Leucemia Linfocítica Crônica de Células B / Inibidores de Proteínas Quinases Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Linfócitos T Citotóxicos / Leucemia Linfocítica Crônica de Células B / Inibidores de Proteínas Quinases Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Ano de publicação: 2018 Tipo de documento: Article